公开(公告)号：US20240181054A1

公开(公告)日：2024-06-06

申请号：US18550205

申请日：2022-03-14

申请人： Synthego Corporation

发明人： Robert DEANS ,  Travis MAURES ,  Yueting ZHENG ,  Jared Carlson STEVERMER ,  Monique DAO ,  Phillip BALZANO ,  Rebecca NUGENT

IPC分类号： A61K39/00 ,  C07K14/74 ,  C12N5/0781 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC分类号： A61K39/4622 ,  A61K39/4612 ,  A61K39/4634 ,  A61K39/464491 ,  C07K14/70539 ,  C12N5/0635 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C07K2319/40 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2800/80

摘要： The application relates to biological components, methods, systems, and kits for modulating immune responses. The disclosed biological components include genetically modified cells comprising an inserted exogenous sequence in a major histocompatibility complex (MHC)-associated gene. The inserted exogenous sequence encodes a peptide and the genetically modified cells express a fusion protein comprising the peptide and at least a portion of the polypeptide encoded by the MHC-associated gene to form a modified MHC complex. The genetically modified cells may present the peptide as an antigen associated with the MHC complex and may be utilized in methods for modulating T cell activity, inducing an immune response, and inducing a tolerogenic response. As such, the disclosed biological components, methods, systems, and kits may be utilized in order to treat and/or prevent a disease or disorder in a subject in need thereof and to screen and validate clinically relevant antigens.